

(2) at least one polypeptide from the early region of a papillomavirus and at least one polypeptide from the late region of a papillomavirus and at least one polypeptide having immunostimulatory activity, or

(3) at least one polypeptide from the early region or late region of a papillomavirus and at least one polypeptide having immunostimulatory activity, wherein said polypeptide from the early region of a papillomavirus [is not fused to the] and said polypeptide from the late region of a papillomavirus and said polypeptide having immunostimulatory activity are expressed recombinantly from independent expression control elements.

32. (Amended) A pharmaceutical composition according to claim 1, wherein said composition comprises:

(a) [a polypeptide from the] a nononcogenic variant of an E6 [region] protein of a human papillomavirus;

(b) [a polypeptide from the] a nononcogenic variant of an E7 [region] protein of a human papillomavirus; and

(c) interleukin 2[;

wherein said polypeptide from the E6 region and said polypeptide from the E7 region are nononcogenic variants of the E6 and E7 proteins of said papillomavirus].

33. (Amended) A pharmaceutical composition according to claim 1, wherein said composition comprises:

- (a) [a polypeptide from the] a nononcogenic variant of an E6 [region] protein of a human papillomavirus;
- (b) [a polypeptide from the] a nononcogenic variant of an E7 [region] protein of a human papillomavirus;
- (c) a polypeptide from the L1 region of a human papillomavirus;
- (d) a polypeptide from the L2 region of a human papillomavirus; and
- (e) interleukin 2[;

wherein said polypeptide from the E6 region and said polypeptide from the E7 region are nononcogenic variants of the E6 and E7 proteins of said papillomavirus].

Kindly add the following new claims:

--34. (New) The pharmaceutical composition of claim 32, wherein said nononcogenic variant of the E6 protein is a variant of HPV-16 E6 having amino acids 111-116 deleted as compared to the native E6 protein.

35. (New) The pharmaceutical composition of claim 32, wherein said nononcogenic variant of the E7 protein is a variant of HPV-16 E7 having amino acids 21-26 deleted as compared to the native E7 protein.